Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Genetic and Non-genetic Correlates of Imatinib Pharmacokinetics and Side Effects of Imatinib in Palestinian Patients with Chronic Myeloid Leukemia.
Adawi DH et al.
Biochemical Genetics, 2025
SNP's use as a potential chemotoxicity stratification tool in breast cancer: from bench to clinic.
Moustafa HAM et al.
Functional & Integrative Genomics, 2025
Analgesic therapy failure in a COMT HPS/HPS diplotype carrier heterozygous for the CYP2D6 *4 allele with fibromyalgia-a case report.
Bollinger A et al.
Pain Reports, 2025
Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.
Mangoura SA et al.
Cancer Chemotherapy and Pharmacology, 2024
The Cytochrome P450 2C8*3 Variant (rs11572080) Is Associated with Improved Asthma Symptom Control in Children and Altered Lipid Mediator Production and Inflammatory Response in Human Bronchial Epithelial Cells.
Almestica-Roberts M et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Meta-analysis of the global distribution of clinically relevant CYP2C8 alleles and their inferred functional consequences.
Camara MD et al.
Human Genomics, 2024
CYP2C8 rs11572080 and CYP3A4 rs2740574 risk genotypes in paclitaxel-treated premenopausal breast cancer patients.
Attia HRM et al.
Scientific Reports, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
G-quadruplex forming sequences in the genes coding for cytochrome P450 enzymes and their potential roles in drug metabolism.
Saad M et al.
Biochimie, 2023
Functional Characterization of Allelic Variations of Human Cytochrome P450 2C8 (V181I, I244V, I331T, and L361F).
Lee YB et al.
International Journal of Molecular Sciences, 2023
The Influence of Cytochrome P450 Polymorphisms on Pharmacokinetic Profiles and Treatment Outcomes Among Malaria Patients in Sub-Saharan Africa: A Systematic Review.
Marwa KJ et al.
Pharmacogenomics and Personalized Medicine, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
Variability of CYP2C8 Polymorphisms in Three Jordanian Populations: Circassians, Chechens and Jordanian-Arabs.
Abudahab S et al.
Journal of Immigrant and Minority Health, 2022
The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals.
Haeggström S et al.
The Pharmacogenomics Journal, 2022
Diclofenac-induced adverse drug reactions and hyperbilirubinemia caused by a variant gene.
Chen ES et al.
The Kaohsiung Journal of Medical Sciences, 2022
Role of cytochrome P450 2C8 genetic polymorphism and epoxygenase uncoupling in periodontal remodelling affecting orthodontic treatment.
Yamoune S et al.
Basic & Clinical Pharmacology & Toxicology, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.
Muñiz P et al.
Frontiers in Immunology, 2022
The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
Chen Z et al.
Pharmacological Reports : Pr, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.
Iannaccone T et al.
Pharmaceuticals (basel, Switzerland), 2021
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate-amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar.
Pernaute-Lau L et al.
Malaria Journal, 2021
Genetic polymorphisms associated with upper gastrointestinal bleeding: a systematic review.
Forgerini M et al.
The Pharmacogenomics Journal, 2021
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Pellegrino B et al.
Esmo Open, 2021
Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.
Hertz DL
Expert Opinion on Drug Metabolism & Toxicology, 2021
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi-Ethnic Allele and Copy Number Variant Detection.
Scott SA et al.
Clinical and Translational Science, 2021
Diabetes and Genetics: A Relationship Between Genetic Risk Alleles, Clinical Phenotypes and Therapeutic Approaches.
Sayed S et al.
Advances in Experimental Medicine and Biology, 2021
Whole-Exome Sequencing in Patients Affected by Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Reveals New Variants Potentially Contributing to the Phenotype.
Fonseca DJ et al.
Pharmacogenomics and Personalized Medicine, 2021
ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.
da Costa Junior LC et al.
European Journal of Clinical Pharmacology, 2020
Genetic associations of docetaxel-based chemotherapy-induced myelosuppression in Chinese Han population.
Ren W et al.
Journal of Clinical Pharmacy and Therapeutics, 2020
CYP3A5*3 and CYP2C8*3 variants influence exposure and clinical outcomes of tacrolimus-based therapy.
Genvigir FDV et al.
Pharmacogenomics, 2020
Assessment of pharmacogenomic SLCO1B1 assay for prediction of neuromuscular pain in type 2 diabetes mellitus and cardiovascular patients: preliminary results.
Licito A et al.
European Review for Medical and Pharmacological Sciences, 2020
Prevalence of CYP2C8*2 and *3 among Eritreans and its Potential Impact on Artesunate/Amodiaquine Treatment.
Habtemikael L et al.
Pharmacogenomics and Personalized Medicine, 2020
Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications.
Marcath LA et al.
The Pharmacogenomics Journal, 2019
Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
Daher A et al.
Malaria Journal, 2019
Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling.
R Arnold W et al.
International Journal of Molecular Sciences, 2019
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients.
Zhou X et al.
Internal Medicine (tokyo, Japan), 2019
Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.
de Castro CL et al.
Archives of Gynecology and Obstetrics, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Assessment of coding region variants in Kuwaiti population: implications for medical genetics and population genomics.
John SE et al.
Scientific Reports, 2018
Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population.
Hiratsuka M et al.
Drug Metabolism and Pharmacokinetics, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018